Silvia G Priori

List of Publications by Year in Descending Order

439 papers	73,668 citations	124 h-index	268 g-index
509 ext. papers	84,335 ext. citations	8.9 avg, IF	6.99 L-index

#	Paper	IF	Citations
439	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment-Authors' reply.. *Europace*, **2022**,	3.9	1
438	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003391	5.2	0
437	Catecholaminergic Polymorphic Ventricular Tachycardia **2022**, 167-183		
436	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With Blockers.. *JAMA Cardiology*, **2022**,	16.2	3
435	Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death. *Bioscience Reports*, **2021**, 41,	4.1	6
434	Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5/5. *Journal of the American College of Cardiology*, **2021**, 77, 2592-2612	15.1	4
433	ESC CONGRESS 2020-the digital experience: expanding the reach of the society. *European Heart Journal*, **2021**, 42, 2812-2813	9.5	
432	Management of Congenital Long-QT Syndrome: Commentary From the Experts. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e009726	6.4	2
431	Left Ventricular Myocardial Work in Patients with Severe Aortic Stenosis. *Journal of the American Society of Echocardiography*, **2021**, 34, 257-266	5.8	11
430	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. *Genetics in Medicine*, **2021**, 23, 47-58	8.1	13
429	Evolving determinants of carotid atherosclerosis vulnerability in asymptomatic patients from the MAGNETIC observational study. *Scientific Reports*, **2021**, 11, 2327	4.9	1
428	Cardiac ryanodine receptor calcium release deficiency syndrome. *Science Translational Medicine*, **2021**, 13,	17.5	18
427	Genotype-Phenotype Correlation of Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003222	5.2	0
426	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). *Europace*, **2021**,	3.9	1
425	Additional diagnostic value of cardiac magnetic resonance feature tracking in patients with biopsy-proven arrhythmogenic cardiomyopathy. *International Journal of Cardiology*, **2021**, 339, 203-210	3.2	3
424	Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time?. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 75, 545-545	0.7	
423	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. *Circulation*, **2020**, 142, 324-338	16.7	27

422	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. *Circulation*, **2020**, 141, 1872-1884	16.7	80
421	Tetrodotoxin-Sensitive Neuronal-Type Na Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. *Journal of the American Heart Association*, **2020**, 9, e015119	6	1
420	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. *Circulation*, **2020**, 142, 513-515	16.7	26
419	An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. *Circulation*, **2020**, 141, 429-439	16.7	15
418	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. *European Heart Journal*, **2020**, 41, 614-617	9.5	6
417	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2020**, 22, 1378-1389	12.3	32
416	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2020**, 22, 1424-1437	12.3	13
415	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. *Journal of the American College of Cardiology*, **2020**, 75, 1772-1784	15.1	18
414	Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients. *Frontiers in Pharmacology*, **2020**, 11, 580481	5.6	2
413	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. *European Heart Journal*, **2020**, 41, 2083-2088	9.5	437
412	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2020**, 22, 92-102	12.3	35
411	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of -Catecholaminergic Polymorphic Ventricular Tachycardia. *Circulation*, **2020**, 142, 932-947	16.7	12
410	Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics. *Science Advances*, **2020**, 6, eaba5345	14.3	11
409	Stabilizer Cell Gene Therapy: A Less-Is-More Strategy to Prevent Cardiac Arrhythmias. *Circulation: Arrhythmia and Electrophysiology*, **2020**, 13, e008420	6.4	2
408	ESC Core Curriculum for the Cardiologist. *European Heart Journal*, **2020**, 41, 3605-3692	9.5	12
407	A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart. *Cell*, **2020**, 183, 94-109.e23	36.2	126
406	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the Gene Associated With Brugada Syndrome. *Frontiers in Physiology*, **2020**, 11, 616819	4.6	6
405	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3 *Circulation*, **2019**, 140, 1188-1204	16.7	36

404	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. *European Journal of Heart Failure*, **2019**, 21, 1383-1397	12.3	20
403	Acute heart failure congestion and perfusion status´-ˆimpact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2019**, 21, 1338-1352	12.3	62
402	Supervised methods to extract clinical events from cardiology reports in Italian. *Journal of Biomedical Informatics*, **2019**, 95, 103219	10.2	9
401	Dilated cardiomyopathy. *Nature Reviews Disease Primers*, **2019**, 5, 32	51.1	143
400	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12,	6.4	5
399	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*, **2019**, 16, e301-e372	6.7	247
398	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1756-1765	15.1	33
397	Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1868-1869	15.1	3
396	Enhancement of Cardiac Store Operated Calcium Entry (SOCE) within Novel Intercalated Disk Microdomains in Arrhythmic Disease. *Scientific Reports*, **2019**, 9, 10179	4.9	21
395	Heritability in genetic heart disease: the role of genetic background. *Open Heart*, **2019**, 6, e000929	3	7
394	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2019**, 16, 1468-1474	6.7	14
393	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. *Heart Rhythm*, **2019**, 16, e373-e407	6.7	73
392	What a Congress!. *European Heart Journal*, **2019**, 40, 3507-3509	9.5	
391	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Europace*, **2019**, 21, 796-802	3.9	7
390	Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation. *Circulation Research*, **2019**, 124, 539-552	15.7	27
389	International Triadin Knockout Syndrome Registry. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002419	5.2	20
388	Genetic risk stratification in cardiac arrhythmias. *Current Opinion in Cardiology*, **2018**, 33, 298-303	2.1	4
387	Interplay Between Genetic Substrate, QTc´Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. *Journal of the American College of Cardiology*, **2018**, 71, 1663-1671	15.1	76

386	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2018**, 15, 1394-1401	6.7	49
385	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). *Heart Rhythm*, **2018**, 15, 716-724	6.7	36
384	Information extraction from Italian medical reports: An ontology-driven approach. *International Journal of Medical Informatics*, **2018**, 111, 140-148	5.3	11
383	Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. *Journal of the American Heart Association*, **2018**, 7,	6	22
382	Gene Therapy to Treat Cardiac Arrhythmias **2018**, 531-540		
381	Timothy Syndrome **2018**, 910-916		0
380	Big Data as a Driver for Clinical Decision Support Systems: A Learning Health Systems Perspective. *Frontiers in Digital Humanities*, **2018**, 5,	2.1	16
379	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. *Heart Rhythm*, **2018**, 15, 1457-1465	6.7	36
378	Inherited Arrhythmias: LQTS/SQTS/CPVT **2018**, 413-435		
377	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. *Human Mutation*, **2018**, 39, 1835-1846	4.7	11
376	Implantable Loop Recorder in Inherited Arrhythmia Diseases: A Critical Tool for Symptom Diagnosis and Advanced Risk Stratification. *JACC: Clinical Electrophysiology*, **2018**, 4, 1372-1374	4.6	8
375	Cardiac Magnetic Resonance in Stable Coronary Artery Disease: Added Prognostic Value to Conventional Risk Profiling. *BioMed Research International*, **2018**, 2018, 2806148	3	2
374	J-Wave Syndromes: Electrocardiographic and Clinical Aspects. *Cardiac Electrophysiology Clinics*, **2018**, 10, 355-369	1.4	8
373	The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome. *JACC: Clinical Electrophysiology*, **2017**, 3, 727-743	4.6	24
372	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (). *Circulation Research*, **2017**, 121, 525-536	15.7	33
371	The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization. *Journal of Cardiovascular Electrophysiology*, **2017**, 28, 1226-1236	2.7	18
370	Genetic causes of sudden cardiac death in the young. *Current Opinion in Cardiology*, **2017**, 32, 253-261	2.1	7
369	Reply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?. *Journal of the American College of Cardiology*, **2017**, 69, 248-249	15.1	1

368	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. *Europace*, **2017**, 19, 139-163	3.9	36
367	Diagnóstico del síndrome de QT largo: valor del ortostatismo. *Revista Espanola De Cardiologia*, **2017**, 70, 898-900	1.5	
366	Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. *Current Opinion in Pediatrics*, **2017**, 29, 552-559	3.2	7
365	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. *Journal of the American College of Cardiology*, **2017**, 70, 3010-3015	15.1	41
364	Suppression of Arrhythmia by Enhancing Mitochondrial Ca Uptake in Catecholaminergic Ventricular Tachycardia Models. *JACC Basic To Translational Science*, **2017**, 2, 737-747	8.7	26
363	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. *European Journal of Preventive Cardiology*, **2017**, 24, 41-69	3.9	110
362	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. *Heart Rhythm*, **2017**, 14, e41-e44	6.7	60
361	Age of First Arrhythmic Event in Brugada Syndrome: Data From the SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) in 678 Patients. *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	39
360	Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. *JAMA Cardiology*, **2017**, 2, 759-766	16.2	80
359	Recurrent Neural Network Architectures for Event Extraction from Italian Medical Reports. *Lecture Notes in Computer Science*, **2017**, 198-202	0.9	4
358	Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. *Cell Death and Disease*, **2016**, 7, e2393	9.8	37
357	Role of the JP45-Calsequestrin Complex on Calcium Entry in Slow Twitch Skeletal Muscles. *Journal of Biological Chemistry*, **2016**, 291, 14555-65	5.4	8
356	hERG Blockade by Iboga Alkaloids. *Cardiovascular Toxicology*, **2016**, 16, 14-22	3.4	18
355	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. *Circulation*, **2016**, 133, 622-30	16.7	138
354	Programmed ventricular stimulation early after myocardial infarction: authors' reply. *Europace*, **2016**, 18, 789-90	3.9	
353	Guía ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevención de la muerte súbita cardiaca. *Revista Espanola De Cardiologia*, **2016**, 69, 176.e1-176.e77	1.5	11
352	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 176	0.7	30
351	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. *Journal of the American College of Cardiology*, **2016**, 67, 1053-1058	15.1	123

350	Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. *Heart Lung and Circulation*, **2016**, 25, 777-83	1.8	26
349	R4496C RyR2 mutation impairs atrial and ventricular contractility. *Journal of General Physiology*, **2016**, 147, 39-52	3.4	16
348	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 937-43	2.7	14
347	Electrocardiographic features of sudden unexpected death in epilepsy. *Epilepsia*, **2016**, 57, e135-9	6.4	25
346	Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 1124-32	2.7	6
345	Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. *Journal of the American College of Cardiology*, **2016**, 68, 2540-2550	15.1	99
344	Gu□ ESC 2016 sobre el diagn□tico y tratamiento de la insuficiencia cardiaca aguda y cr□tica. *Revista Espanola De Cardiologia*, **2016**, 69, 1167.e1-1167.e85	1.5	91
343	Neuronal Na Channels Are Integral Components of Pro-arrhythmic Na/Ca Signaling Nanodomain That Promotes Cardiac Arrhythmias During □adrenergic Stimulation. *JACC Basic To Translational Science*, **2016**, 1, 251-266	8.7	28
342	Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1. *European Journal of Medical Genetics*, **2015**, 58, 332-5	2.6	11
341	Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. *Current Opinion in Genetics and Development*, **2015**, 33, 17-24	4.9	17
340	Gene therapy to treat cardiac arrhythmias. *Nature Reviews Cardiology*, **2015**, 12, 531-46	14.8	27
339	Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. *International Journal of Cardiology*, **2015**, 190, 393-402	3.2	43
338	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *European Heart Journal*, **2015**, 36, 2793-2867	3.9	426
337	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *European Heart Journal*, **2015**, 36, 2793-2867	9.5	2187
336	Genetics of sudden cardiac death. *Circulation Research*, **2015**, 116, 1919-36	15.7	161
335	From decision to shared-decision: Introducing patients' preferences into clinical decision analysis. *Artificial Intelligence in Medicine*, **2015**, 65, 19-28	7.4	21
334	Use of whole exome sequencing for the identification of Ito-based arrhythmia mechanism and therapy. *Journal of the American Heart Association*, **2015**, 4,	6	13
333	Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release. *Cardiovascular Research*, **2015**, 106, 143-52	9.9	31

332	Genetically engineered SCN5A mutant pig hearts exhibit conduction defects and arrhythmias. *Journal of Clinical Investigation*, **2015**, 125, 403-12	15.9	68
331	Genetic testing to predict sudden cardiac death: current perspectives and future goals. *Indian Heart Journal*, **2014**, 66 Suppl 1, S58-60	1.6	12
330	Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotype. *Human Molecular Genetics*, **2014**, 23, 4875-86	5.6	52
329	Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload. *Journal of the American College of Cardiology*, **2014**, 63, 1569-79	15.1	37
328	Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. *Circulation*, **2014**, 129, 1092-103	16.7	242
327	Congenital Long QT Syndrome Type 3. *Cardiac Electrophysiology Clinics*, **2014**, 6, 705-713	1.4	3
326	Sodium Current Disorders. *Cardiac Electrophysiology Clinics*, **2014**, 6, 825-833	1.4	
325	Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. *Circulation*, **2014**, 129, 2673-81	16.7	64
324	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *European Heart Journal*, **2014**, 35, 2733-79	9.5	2361
323	Epidemiology of sudden cardiac death in Cameroon: rationale and design of the Douala-SUD survey. *Archives of Cardiovascular Diseases*, **2014**, 107, 433-42	2.7	7
322	Novel insight into the natural history of short QT syndrome. *Journal of the American College of Cardiology*, **2014**, 63, 1300-1308	15.1	147
321	Timothy Syndrome **2014**, 953-957		1
320	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. *Expert Review of Cardiovascular Therapy*, **2014**, 12, 499-519	2.5	31
319	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. *European Heart Journal*, **2014**, 35, 3250-7	9.5	66
318	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. *Journal of Arrhythmia*, **2014**, 30, 29-47	1.5	8
317	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. *Journal of Arrhythmia*, **2014**, 30, 1-28	1.5	11
316	Rationale and design of the Pan-African Sudden Cardiac Death survey: the Pan-African SCD study. *Cardiovascular Journal of Africa*, **2014**, 25, 176-84	0.7	11
315	Inheritable Phenotypes Associated With Altered Intracellular Calcium Regulation **2014**, 521-528		

314	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. *Heart Rhythm*, **2013**, 10, e85-108	6.7	123
313	HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*, **2013**, 10, 1932-63	6.7	1211
312	KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 4291-6	11.5	108
311	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. *Europace*, **2013**, 15, 1389-406	3.9	379
310	Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca2+ release in a genetic model of arrhythmia. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10312-7	11.5	42
309	Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2013**, 113, 142-52	15.7	37
308	CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. *Cell Death and Disease*, **2013**, 4, e843	9.8	92
307	Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. *Journal of Clinical Investigation*, **2013**, 123, 84-91	15.9	53
306	Catecholaminergic Polymorphic Ventricular Tachycardia **2013**, 551-560		
305	L-Type Calcium Channel Disease **2013**, 209-217		1
304	Genetics and Arrhythmias: Diagnostic and Prognostic Applications. *Revista Espanola De Cardiologia (English Ed)*, **2012**, 65, 278-286	0.7	
303	Genetics and arrhythmias: diagnostic and prognostic applications. *Revista Espanola De Cardiologia*, **2012**, 65, 278-86	1.5	31
302	An ICT infrastructure to integrate clinical and molecular data in oncology research. *BMC Bioinformatics*, **2012**, 13 Suppl 4, S5	3.6	21
301	Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14, 29	6.9	26
300	Role of Mapping and Ablation in Genetic Diseases: Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia **2012**, 644-655		1
299	Inherited calcium channelopathies in the pathophysiology of arrhythmias. *Nature Reviews Cardiology*, **2012**, 9, 561-75	14.8	139
298	Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. *Journal of the American College of Cardiology*, **2012**, 59, 37-45	15.1	409
297	Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Trends in Cardiovascular Medicine*, **2012**, 22, 35-9	6.9	9

296	Genetic Mechanisms of Arrhythmia **2012**, 601-623		
295	Risk Stratification in the Long QT Syndrome. *Cardiac Electrophysiology Clinics*, **2012**, 4, 53-60	1.4	1
294	How to Interpret Results of Genetic Testing and Counsel Families. *Cardiac Electrophysiology Clinics*, **2012**, 4, 97-101	1.4	
293	Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias. *Circulation Research*, **2012**, 110, 663-8	15.7	55
292	A clinical approach to inherited arrhythmias. *Circulation: Cardiovascular Genetics*, **2012**, 5, 581-90		24
291	Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation. *Circulation*, **2012**, 125, 2027-34	16.7	97
290	Genetics of ion-channel disorders. *Current Opinion in Cardiology*, **2012**, 27, 242-52	2.1	30
289	Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2012**, 126, 392-401	16.7	59
288	The European CRT Survey: 1 year (9-15 months) follow-up results. *European Journal of Heart Failure*, **2012**, 14, 61-73	12.3	74
287	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [Europace 2011;13:1077-109, doi: 10.1093/europace/eur245]. *Europace*, **2012**, 14, 277-277	3.9	1
286	Role of calmodulin kinase in catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2011**, 8, 1601-5	6.7	6
285	Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. *Journal of the American College of Cardiology*, **2011**, 57, 51-9	15.1	205
284	Overexpression of CaMKII□ in RyR2R4496C+/- knock-in mice leads to altered intracellular Ca2+ handling and increased mortality. *Journal of the American College of Cardiology*, **2011**, 57, 469-79	15.1	28
283	Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. *Journal of the American College of Cardiology*, **2011**, 57, 941-50	15.1	84
282	HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Heart Rhythm*, **2011**, 8, 1308-39	6.7	737
281	Intracellular Calcium Handling and Inherited Arrhythmogenic Diseases **2011**, 387-408		
280	Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. *Journal of Molecular and Cellular Cardiology* , **2011**, 50, 214-22	5.8	95
279	ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *European Heart Journal*, **2011**, 32, 3147-97	9.5	1167

278	HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). *Europace*, **2011**, 13, 1077-109	3.9	557
277	RyRCa2+ leak limits cardiac Ca2+ window current overcoming the tonic effect of calmodulinin mice. *PLoS ONE*, **2011**, 6, e20863	3.7	10
276	ST-segment elevation in the setting of a febrile illness. *Annals of Noninvasive Electrocardiology*, **2011**, 16, 303-4; discussion 304-7	1.5	3
275	The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. *European Journal of Heart Failure*, **2011**, 13, 974-83	12.3	73
274	Genetic determinants of cardiac (electric) conduction. *Circulation Research*, **2011**, 108, 402-3	15.7	2
273	Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. *Circulation*, **2011**, 123, 1911-8	16.7	111
272	Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. *Circulation Research*, **2011**, 109, 291-5	15.7	84
271	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*, **2011**, 123, e269-367	16.7	643
270	R engine cell: integrating R into the i2b2 software infrastructure. *Journal of the American Medical Informatics Association: JAMIA*, **2011**, 18, 314-7	8.6	14
269	Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries. *Europace*, **2011**, 13 Suppl 2, ii18-20	3.9	21
268	The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. *Europace*, **2011**, 13, 1445-53	3.9	23
267	Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H288-99	5.2	38
266	Genetics of sudden death: focus on inherited channelopathies. *European Heart Journal*, **2011**, 32, 2109-18	9.5	90
265	Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. *Circulation Research*, **2011**, 108, 871-83	15.7	314
264	Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. *Circulation Research*, **2010**, 106, 1374-83	15.7	61
263	Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. *Circulation Research*, **2010**, 107, 512-9	15.7	81
262	The fifteen years of discoveries that shaped molecular electrophysiology: time for appraisal. *Circulation Research*, **2010**, 107, 451-6	15.7	30
261	In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. *Circulation Research*, **2010**, 107, 1483-9	15.7	76

260	Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. *Circulation*, **2010**, 122, 1272-82	16.7	209
259	Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. *Cardiovascular Research*, **2010**, 87, 50-9	9.9	74
258	Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. *Journal of the American College of Cardiology*, **2010**, 55, 2745-52	15.1	143
257	2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. *Europace*, **2010**, 12, 1526-36	3.9	158
256	Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. *European Neuropsychopharmacology*, **2010**, 20, 829-38	1.2	18
255	Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2010**, 7, 1122-8	6.7	64
254	When is genetic testing useful in patients suspected to have inherited cardiac arrhythmias?. *Current Opinion in Cardiology*, **2010**, 25, 37-45	2.1	6
253	Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening. *Prenatal Diagnosis*, **2010**, 30, 229-34	3.2	25
252	Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. *European Heart Journal*, **2009**, 30, 2241-8	9.5	128
251	The European cardiac resynchronization therapy survey. *European Heart Journal*, **2009**, 30, 2450-60	9.5	178
250	Routine electrocardiogram and medical history in syncope: a simple approach can identify most high-risk patients. *Europace*, **2009**, 11, 1411-2	3.9	3
249	High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". *Circulation*, **2009**, 119, 215-21	16.7	235
248	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. *European Journal of Heart Failure*, **2009**, 11, 1143-51	12.3	95
247	European cardiac resynchronization therapy survey: rationale and design. *European Journal of Heart Failure*, **2009**, 11, 326-30	12.3	12
246	Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2009**, 104, 201-9, 12p following 209	15.7	114
245	Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. *Circulation: Arrhythmia and Electrophysiology*, **2009**, 2, 6-15	6.4	111
244	Charcot-Marie-Tooth type 1a in a child with Long QT syndrome. *European Journal of Paediatric Neurology*, **2009**, 13, 459-62	3.8	5
243	The genetics of cardiomyopathy: genotyping and genetic counseling. *Current Treatment Options in Cardiovascular Medicine*, **2009**, 11, 433-46	2.1	10

242	The long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. *PACE - Pacing and Clinical Electrophysiology*, **2009**, 32 Suppl 2, S52-7	1.6	5
241	To replace or not to replace: a systematic approach to respond to device advisories. *Journal of Cardiovascular Electrophysiology*, **2009**, 20, 164-70	2.7	16
240	Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. *Journal of Molecular and Cellular Cardiology*, **2009**, 46, 149-59	5.8	51
239	Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. *Journal of the American College of Cardiology*, **2009**, 54, 832-7	15.1	70
238	Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). *Heart Rhythm*, **2009**, 6, 1335-41	6.7	272
237	Sodium channel mutations and arrhythmias. *Nature Reviews Cardiology*, **2009**, 6, 337-48	14.8	226
236	Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation. *Heart Rhythm*, **2009**, 6, 1652-9	6.7	90
235	IK1 modulates the U-wave: insights in a 100-year-old enigma. *Heart Rhythm*, **2009**, 6, 393-400	6.7	25
234	Clinical spectrum of patients with a Brugada ECG. *Current Opinion in Cardiology*, **2009**, 24, 74-81	2.1	42
233	Catecholaminergic polymorphic ventricular tachycardia. *Progress in Cardiovascular Diseases*, **2008**, 51, 23-30	8.5	130
232	HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. *Heart Rhythm*, **2008**, 5, 907-25	6.7	214
231	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Fail. *Europace*, **2008**, 10, 707-25	3.9	177
230	Risk of death in the long QT syndrome when a sibling has died. *Heart Rhythm*, **2008**, 5, 831-6	6.7	55
229	Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. *Europace*, **2008**, 10, 336-46	3.9	183
228	Long-QT syndrome after age 40. *Circulation*, **2008**, 117, 2192-201	16.7	117
227	Luminal Ca2+ regulation of single cardiac ryanodine receptors: insights provided by calsequestrin and its mutants. *Journal of General Physiology*, **2008**, 131, 325-34	3.4	106
226	Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. *Circulation*, **2008**, 117, 2184-91	16.7	229
225	Successful treatment of heart failure with devices requires collaboration. *European Journal of Heart Failure*, **2008**, 10, 1229-35	12.3	21

224	Therapeutic strategies for long-QT syndrome: does the molecular substrate matter?. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 290-7	6.4	49
223	Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. *Circulation Research*, **2008**, 103, 298-306	15.7	110
222	Catecholaminergic polymorphic ventricular tachycardia-related mutations R33Q and L167H alter calcium sensitivity of human cardiac calsequestrin. *Biochemical Journal*, **2008**, 413, 291-303	3.8	41
221	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *European Heart*	9.5	2298
220	Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. *Cardiovascular Research*, **2008**, 77, 293-301	9.9	47
219	L-type Calcium Channel Disease **2008**, 187-193		
218	Catecholaminergic Polymorphic Ventricular Tachycardia **2008**, 536-544		
217	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *European Heart Journal*, **2007**, 28, 2375-414	9.5	1029
216	Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. *Circulation Research*, **2007**, 101, 1039-48	15.7	215
215	Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2007**, 4, 675-8	6.7	109
214	Long QT syndrome in adults. *Journal of the American College of Cardiology*, **2007**, 49, 329-37	15.1	311
213	Long QT syndrome and pregnancy. *Journal of the American College of Cardiology*, **2007**, 49, 1092-8	15.1	233
212	In silico assessment of Y1795C and Y1795H SCN5A mutations: implication for inherited arrhythmogenic syndromes. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H56-65	5.2	20
211	Cardiovascular risks of atypical antipsychotic drug treatment. *Pharmacoepidemiology and Drug Safety*, **2007**, 16, 882-90	2.6	52
210	Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. *Journal of Cardiovascular Electrophysiology*, **2007**, 18, 791-7	2.7	101
209	Outcome parameters for trials in atrial fibrillation: executive summary. *European Heart Journal*, **2007**, 28, 2803-17	9.5	267
208	Catecholaminergic polymorphic ventricular tachycardia. *Herz*, **2007**, 32, 212-7	2.6	23
207	Clinical diagnosis of long QT syndrome: back to the caliper. *European Heart Journal*, **2007**, 28, 527-8	9.5	13

206	Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. *Circulation*, **2007**, 116, 1137-44	16.7	159
205	Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. *Europace*, **2007**, 9, 1006-23	3.9	197
204	European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *European Journal of Cardiovascular Prevention and Rehabilitation*, **2007**, 14 Suppl 2, S1-113		751
203	Universal definition of myocardial infarction. *Circulation*, **2007**, 116, 2634-53	16.7	1953
202	The Brugada syndrome. *Current Opinion in Cardiology*, **2007**, 22, 163-70	2.1	21
201	The fight against sudden cardiac death: consensus guidelines as a reference. *Country Review Ukraine*, **2007**, 9, I50-I58		2
200	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. *Atherosclerosis*, **2007**, 194, 1-45	3.1	190
199	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *European Journal of Cardiovascular Prevention and Rehabilitation*,		309
198	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *European Heart Journal*, **2007**, 28, 230-68	9.5	1105
197	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *European Heart Journal*, **2007**, 28, 88-136	9.5	889
196	Genetics of Inherited Arrhythmias **2007**, 502-513		
195	Computer simulation of wild-type and mutant human cardiac Na+ current. *Medical and Biological Engineering and Computing*, **2006**, 44, 35-44	3.1	9
194	Gene-specific therapy for inherited arrhythmogenic diseases **2006**, 110, 1-13		23
193	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of	9.5	360
192	European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance. *Europace*, **2006**, 8, 313-22 Rhythm Associat. *European Heart Journal*, **2006**, 27, 2099-140	3.9	19
191	Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1249-54	27.4	216
190	The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. *European Heart Journal*, **2006**, 27, 1338-40	9.5	129
189	Cost-effectiveness of neonatal ECG screening for the long QT syndrome. *European Heart Journal*, **2006**, 27, 1824-32	9.5	101

188	Female predominance and transmission distortion in the long-QT syndrome. *New England Journal of Medicine*, **2006**, 355, 2744-51	59.2	63
187	Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. *Circulation Research*, **2006**, 99, 292-8	15.7	256
186	Letter regarding article by Coronel et al, "right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study". *Circulation*, **2006**, 113, e726; author reply 726-7	16.7	3
185	Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. *Circulation Research*, **2006**, 98, 1151-8	15.7	163
184	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart. *Circulation*, **2006**, 114, e385-484	16.7	901
183	Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2006**, 13, 876-85		122
182	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart R. *Europace*, **2006**, 8, 746-837	3.9	392
181	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial	9.5	479
180	Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2006**, 114, 1012-9	16.7	169
179	C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon. *Human Molecular Genetics*, **2006**, 15, 2888-902	5.6	41
178	Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. *European Heart Journal*, **2006**, 27, 994-1005	9.5	260
177	Role of genetic analyses in cardiology: part I: mendelian diseases: cardiac channelopathies. *Circulation*, **2006**, 113, 1130-5	16.7	79
176	ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation*, **2006**, 114, e257-354	16.7	1653
175	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. *European Heart Journal*, **2006**, 27, 1341-81	9.5	981
174	ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular	15.1	972
173	Arrhythmogenic Mechanism of Catecholaminergic Polymorphic Ventricular Tachycardia. *Journal of Arrhythmia*, **2006**, 22, 202-208	1.5	2
172	Current Strategies to Diminish the Impact of Cardiovascular Diseases in Women. *Revista Espanola De Cardiologia (English Ed)*, **2006**, 59, 1190-1193	0.7	
171	Estrategias actuales para reducir el impacto de las enfermedades cardiovasculares en la mujer. *Revista Espanola De Cardiologia*, **2006**, 59, 1190-1193	1.5	4

170	Brugada syndrome. *Orphanet Journal of Rare Diseases*, **2006**, 1, 35	4.2	28
169	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines	15.1	865
168	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation)	3.9	530
167	Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. *Journal of Cardiovascular Medicine*, **2006**, 7, 250-6	1.9	25
166	Endocardial Implantation of a Cardioverter Defibrillator in Early Childhood. *Journal of Cardiovascular Electrophysiology*, **2006**, 060118052427050-???	2.7	
165	Evidence-based vs. 'impressionist' medicine: how best to implement guidelines. *European Heart Journal*, **2005**, 26, 1155-8	9.5	31
164	Evidence-based vs. Impressionist medicine: how best to implement guidelines: reply. *European Heart Journal*, **2005**, 26, 2474-2475	9.5	
163	Gender-specific prescription for cardiovascular diseases?. *European Heart Journal*, **2005**, 26, 1571-2	9.5	29
162	Catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2005**, 2, 550-4	6.7	69
161	Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the	9.5	853
160	Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. *European Heart Journal*, **2005**, 26, 1422-45	9.5	675
159	Psychological stress preceding idiopathic ventricular fibrillation. *Psychosomatic Medicine*, **2005**, 67, 359-65	3.7	38
158	Endocardial implantation of a cardioverter defibrillator in early childhood. *Journal of Cardiovascular Electrophysiology*, **2005**, 16, 1381-3	2.7	4
157	Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. *JAMA - Journal of the American Medical Association*, **2005**, 294, 2975-80	27.4	346
156	A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. *Circulation Research*, **2005**, 96, 800-7	15.7	495
155	Intracellular calcium handling dysfunction and arrhythmogenesis: a new challenge for the electrophysiologist. *Circulation Research*, **2005**, 97, 1077-9	15.7	25
154	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. *European Heart Journal*, **2005**, 26, 384-416	9.5	950
153	Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. *Circulation Research*, **2005**, 96, e77-82	15.7	204

152	Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. *Circulation*, **2005**, 112, 3680-7	16.7	267
151	Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. *Journal of Clinical Investigation*, **2005**, 115, 2033-8	15.9	70
150	Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing?. *Circulation*, **2005**, 112, 279-92; discussion 279-92	16.7	12
149	ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *European Heart Journal*, **2004**, 25, 437-45	9.5	53
148	Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. *Circulation*, **2004**, 109, 1826-33	16.7	503
147	Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. *Circulation Research*, **2004**, 94, 140-5	15.7	69
146	Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1341-4	27.4	445
145	Expert consensus document on beta-adrenergic receptor blockers. *European Heart Journal*, **2004**, 25, 1341-62	9.5	365
144	Images in cardiovascular medicine. Endocardial implantation of a cardioverter-defibrillator in a 13-month-old child affected by long-QT syndrome and syndactyly. *Circulation*, **2004**, 110, e525-7	16.7	6
143	Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. *European Heart Journal*, **2004**, 25, 166-81	9.5	245
142	Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17533-8	11.5	299
141	Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. *Circulation Research*, **2004**, 94, 471-7	15.7	147
140	A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9137-42	11.5	264
139	Genetics of cardiac arrhythmias and sudden cardiac death. *Annals of the New York Academy of Sciences*, **2004**, 1015, 96-110	6.5	69
138	Catecholaminergic polymorphic ventricular tachycardia, recurrent syncope, and implantable loop recorder. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 729	2.7	19
137	Drug-induced torsades de pointes and implications for drug development. *Journal of Cardiovascular Electrophysiology*, **2004**, 15, 475-95	2.7	272
136	Policy statement: ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. *Resuscitation*, **2004**, 60, 245-52	4	24
135	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *European Heart Journal*, **2004**, 25, 2243-78	9.5	665

134	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi□ de la angiotensina en la enfermedad cardiovascular. *Revista Espanola De Cardiologia*, **2004**, 57, 1213-1232	1.5	1
133	Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. *Heart Rhythm*, **2004**, 1, 276-83	6.7	136
132	Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. *Journal of the American College of Cardiology*, **2004**, 44, 117-25	15.1	111
131	Guidelines on management (diagnosis and treatment) of syncope-update 2004. Executive Summary. *European Heart Journal*, **2004**, 25, 2054-72	9.5	205
130	Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell*, **2004**, 119, 19-31	56.2	1182
129	Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. *European Heart Journal*, **2004**, 25, 267-76	9.5	434
128	Postmortem molecular analysis in victims of sudden unexplained death. *American Journal of Forensic Medicine and Pathology*, **2004**, 25, 182-4	1	39
127	Catecholaminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol. *Pediatric Emergency Care*, **2004**, 20, 175-177	1.4	23
126	Long QT Syndrome **2004**, 740-744		
125	Genetics of Long QT, Brugada, and Other Channelopathies **2004**, 462-470		8
124	Catecholaminergic Polymorphic Ventricular Tachycardia and Short-coupled Torsades de Pointes **2004**, 633-639		8
123	Long QT Syndrome: Genotype-Phenotype Correlations **2004**, 651-659		20
122	Loss of function associated with novel mutations of the SCN5A gene in patients with Brugada syndrome. *Canadian Journal of Cardiology*, **2004**, 20, 425-30	3.8	22
121	Management of grown up congenital heart disease. *European Heart Journal*, **2003**, 24, 1035-84	9.5	345
120	ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias□Executive summary A Report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)Developed in collaboration with NASPE□Heart Rhythm Society. *European Heart Journal*, **2003**, 24, 1857-1897	9.5	60
119	Medical Practice Guidelines. Separating science from economics. *European Heart Journal*, **2003**, 24, 1962-4	9.5	20
118	Risk stratification in the long-QT syndrome. *New England Journal of Medicine*, **2003**, 348, 1866-74	59.2	1090
117	Inherited arrhythmia syndromes: applying the molecular biology and genetic to the clinical management. *Journal of Interventional Cardiac Electrophysiology*, **2003**, 9, 93-101	2.4	25

116	A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 407-11	2.7	89
115	Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1149-53	2.7	63
114	How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1120-1	2.7	96
113	Flecainide test in Brugada syndrome: a reproducible but risky tool. *PACE - Pacing and Clinical Electrophysiology*, **2003**, 26, 338-41	1.6	79
112	Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. *Journal of the American College of Cardiology*, **2003**, 41, 633-42	15.1	179
111	Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. *Journal of the American College of Cardiology*, **2003**, 42, 103-9	15.1	224
110	American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *Journal of the American College of Cardiology*, **2003**, 42, 1687-713	15.1	1187
109	ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with	15.1	552
108	FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. *Cell*, **2003**, 113, 829-40	56.2	589
107	Preventing sudden death: the role of the internist. *European Journal of Internal Medicine*, **2003**, 14, 75-76	3.9	1
106	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation*, **2003**, 108, 1664-72	16.7	1985
105	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. *Circulation*, **2003**, 108, 1772-8	16.7	886
104	ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). *Circulation*, **2003**, 108, 1871-909	16.7	437
103	Cardiac sodium channel diseases. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 439-44	5.9	24
102	To the editor. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 1131-3	2.7	4
101	The Long QT Syndrome. *Contemporary Cardiology*, **2003**, 169-185	0.1	
100	Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. *Journal of Cellular Physiology*, **2002**, 190, 1-6	7	165
99	Programmed electrical stimulation in Brugada syndrome: how reproducible are the results?. *Journal of Cardiovascular Electrophysiology*, **2002**, 13, 880-7	2.7	47

98	Romano-Ward and other congenital long QT syndromes. *Cardiovascular Drugs and Therapy*, **2002**, 16, 19-23	3.9	1
97	Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. *Cardiovascular Drugs and Therapy*, **2002**, 16, 89-92	3.9	20
96	Variable expression of long QT syndrome among gene carriers from families with five different HERG mutations. *Annals of Noninvasive Electrocardiology*, **2002**, 7, 40-6	1.5	27
95	Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2002**, 106, 69-74	16.7	937
94	Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. *Circulation*, **2002**, 105, 794-9	16.7	306
93	Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. *European Heart Journal*, **2002**, 23, 975-83	9.5	90
92	Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation*, **2002**, 106, 2514-9	16.7	631
91	Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation*, **2002**, 105, 1342-7	16.7	805
90	A novel SCN5A mutation associated with long QT-3: altered inactivation kinetics and channel dysfunction. *Physiological Genomics*, **2002**, 10, 191-7	3.6	59
89	Genetics of ventricular tachycardia. *Current Opinion in Cardiology*, **2002**, 17, 222-8	2.1	9
88	Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. *Journal of the American College of Cardiology*, **2002**, 39, 1984-91	15.1	65
87	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *Journal of Clinical Investigation*, **2002**, 110, 1201-1209	15.9	162
86	Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. *Journal of Clinical Investigation*, **2002**, 110, 1201-9	15.9	67
85	GPIIb/IIIa polymorphism in patients with myocardial infarction. *Acta Cardiologica*, **2002**, 57, 32-3	0.9	1
84	Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 455-61	2.7	74
83	Foretelling the future in Brugada syndrome: do we have the crystal ball?. *Journal of Cardiovascular Electrophysiology*, **2001**, 12, 1008-9	2.7	13
82	Task Force on Sudden Cardiac Death of the European Society of Cardiology. *European Heart Journal* , **2001**, 22, 1374-450	9.5	520
81	The long QT syndrome. *Europace*, **2001**, 3, 16-27	3.9	40

80	Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. *Journal of Biological Chemistry*, **2001**, 276, 30623-30	5.4	151
79	Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. *Circulation Research*, **2001**, 88, 740-5	15.7	105
78	Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*, **2001**, 103, 89-95	16.7	1363
77	Clinical implications for affected parents and siblings of probands with long-QT syndrome. *Circulation*, **2001**, 104, 557-62	16.7	61
76	Carbon monoxide cardiotoxicity. *Journal of Toxicology: Clinical Toxicology*, **2001**, 39, 35-44		80
75	Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. *Journal of the American College of Cardiology*, **2001**, 37, 911-9	15.1	97
74	Cardiac damage in pediatric carbon monoxide poisoning. *Journal of Toxicology: Clinical Toxicology*, **2001**, 39, 45-51		16
73	Molecular diagnosis in a child with sudden infant death syndrome. *Lancet, The*, **2001**, 358, 1342-3	40	135
72	Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. *Circulation*, **2001**, 103, 196-200	16.7	1101
71	Concealed arrhythmogenic syndromes: the hidden substrate of idiopathic ventricular fibrillation?. *Cardiovascular Research*, **2001**, 50, 218-23	9.9	28
70	Inferior vena cava loop of the implantable cardioverter defibrillator endocardial lead: a possible solution of the growth problem in pediatric implantation. *PACE - Pacing and Clinical Electrophysiology*, **2000**, 23, 2108-12	1.6	23
69	Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 691-6	2.7	280
68	Long QT and Brugada syndromes: from genetics to clinical management. *Journal of Cardiovascular Electrophysiology*, **2000**, 11, 1174-8	2.7	19
67	Significance of QT dispersion in the long QT syndrome. *Progress in Cardiovascular Diseases*, **2000**, 42, 345-50	8.5	19
66	Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. *American Journal of Cardiology*, **2000**, 85, 457-61	3	61
65	Mechanisms of I(Ks) suppression in LQT1 mutants. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H3003-11	5.2	53
64	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H1748-56	5.2	74
63	A common polymorphism associated with antibiotic-induced cardiac arrhythmia. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 10613-8	11.5	411

62	Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. *Circulation*, **2000**, 101, 616-23	16.7	646
61	Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. *Circulation*, **2000**, 102, 2849-55	16.7	352
60	A molecular link between the sudden infant death syndrome and the long-QT syndrome. *New England Journal of Medicine*, **2000**, 343, 262-7	59.2	296
59	Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. *Circulation*, **2000**, 102, 2509-15	16.7	420
58	Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. *Circulation*, **2000**, 102, 1178-85	16.7	1031
57	The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. *Circulation*, **2000**, 102, 945-7	16.7	211
56	Brugada syndrome and sudden cardiac death in children. *Lancet, The*, **2000**, 355, 808-9	40	198
55	Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome. *Circulation*, **1999**, 99, 1344-7	16.7	65
54	Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. *Human Molecular Genetics*, **1999**, 8, 1499-507	5.6	149
53	Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. *Circulation*, **1999**, 99, 674-81	16.7	114
52	Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. *Circulation*, **1999**, 99, 518-28	16.7	257
51	Idiopathic Ventricular Fibrillation. *Journal of Interventional Cardiac Electrophysiology*, **1999**, 3, 198-201		2
50	Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. *American Journal of Cardiology*, **1999**, 84, 876-9	3	186
49	Low penetrance in the long-QT syndrome: clinical impact. *Circulation*, **1999**, 99, 529-33	16.7	650
48	Exploring the hidden danger of noncardiac drugs. *Journal of Cardiovascular Electrophysiology*, **1998**, 9, 1114-6	2.7	36
47	The Long QT Syndrome. *Annals of Noninvasive Electrocardiology*, **1998**, 3, 63-73	1.5	1
46	New mutations in the KVLQT1 potassium channel that cause long-QT syndrome. *Circulation*, **1998**, 97, 1264-9	16.7	77
45	Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *New England Journal of Medicine*, **1998**, 339, 960-5	59.2	628

44	A recessive variant of the Romano-Ward long-QT syndrome?. *Circulation*, **1998**, 97, 2420-5	16.7	120
43	Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation*, **1998**, 97, 2237-44	16.7	377
42	Molecular biology of the long QT syndrome: impact on management. *PACE - Pacing and Clinical Electrophysiology*, **1997**, 20, 2052-7	1.6	32
41	Idiopathic Ventricular Fibrillation: Epidemiology, Pathophysiology, Primary Prevention, Immediate Evaluation and Management, Long-Term Evaluation and Management, Experimental and Theoretical Developments. *Journal of Interventional Cardiac Electrophysiology*, **1997**, 1, 244-247		3
40	Evaluation of the spatial aspects of T-wave complexity in the long-QT syndrome. *Circulation*, **1997**, 96, 3006-12	16.7	114
39	Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. *Circulation Research*, **1996**, 78, 1009-15	15.7	115
38	Left cardiac sympathetic denervation in long QT syndrome patients. *Journal of Interventional Cardiology*, **1995**, 8, 776-81	1.8	7
37	Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. *Human Molecular Genetics*, **1995**, 4, 1603-7	5.6	275
36	Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. *Journal of the American College of Cardiology*, **1995**, 25, 1609-14	15.1	39
35	Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. *Circulation*, **1995**, 92, 3381-6	16.7	532
34	Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. *Circulation*, **1994**, 89, 1681-9	16.7	321
33	Torsade de pointes. Mechanisms and management. *Drugs*, **1994**, 47, 51-65	12.1	100
32	Electrophysiologic mechanisms involved in the development of torsades de pointes. *Cardiovascular Drugs and Therapy*, **1991**, 5, 203-12	3.9	16
31	Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium. *Cardiovascular Drugs and Therapy*, **1991**, 5 Suppl 1, 67-76	3.9	3
30	Influence of hypoxia on adrenergic modulation of triggered activity in isolated adult canine myocytes. *Circulation*, **1991**, 83, 248-59	16.7	24
29	The Importance of □Adrenergic Stimulation of Cardiac Tissue and its Contribution to Arrhythmogenesis During Ischemia. *Journal of Cardiovascular Electrophysiology*, **1990**, 1, 529-542	2.7	5
28	Early afterdepolarizations induced in vivo by reperfusion of ischemic myocardium. A possible mechanism for reperfusion arrhythmias. *Circulation*, **1990**, 81, 1911-20	16.7	59
27	Efficacy and safety of flecainide in low-risk patients with chronic ventricular arrhythmias: a two-year follow-up. *American Heart Journal*, **1989**, 117, 1258-64	4.9	6

26	Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: effect of nifedipine. *American Heart Journal*, **1988**, 116, 37-43	4.9	24
25	Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation. *Circulation*, **1988**, 78, 178-85	16.7	133
24	Multiple comparison of several antiarrhythmic agents by acute oral drug testing in patients with chronic ventricular arrhythmias. *European Heart Journal*, **1988**, 9, 462-70	9.5	4
23	Protective effect of vagal stimulation on reperfusion arrhythmias in cats. *Circulation Research*, **1987**, 61, 429-35	15.7	160
22	Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing. *American Journal of Cardiology*, **1987**, 60, 1068-72	3	11
21	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. *Journal of the American College of Cardiology*, **1986**, 8, 661-8	15.1	27
20	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. *American Heart Journal*, **1985**, 109, 932-6	4.9	8
19	Genetics, genomics and proteomics in sudden cardiac death70-89		
18	Epidemiology of Cardiac Arrest1-20		1
17	Drug-Induced Sudden Death177-188		2
16	Cost-Effectiveness of Implantable Cardioverter-Defibrillators263-279		
15	Arrhythmogenic Mechanisms33-46		
14	Inherited Arrhythmogenic Diseases132-146		0
13	Sudden Cardiac Death and Valvular Heart Diseases147-161		
12	Sudden Death in Athletes189-202		
11	Pharmacology of Sudden Cardiac Death203-219		
10	Implantable Devices220-236		
9	Sudden Cardiac Death: Ablation237-248		

8	External Automated Defibrillators249-262		
7	Genetic Predisposition and Pathology of Sudden Cardiacdeath21-32		
6	Risk Stratification for SCD47-61		1
5	Autonomic Nervous System: Emerging Concepts and Clinical Applications62-73		
4	Clinical Characteristics of Sudden Cardiac Death Victims and Precipitating Events74-87		0
3	The Cardiomyopathies109-131		
2	Genetics of Long QT and Short QT Syndromes1-6		
1	Digital transformation of major scientific meetings induced by the COVID-19 pandemic: insights from the ESC 2020 annual congress. *European Heart Journal Digital Health*,	2.3	78